Reading the tape
NASDAQ: MRVI
Maravai LifeSciences Holdings, Inc.
Healthcare · Biotechnology
Market Cap
$1.04B
52w High
$4.11
52w Low
$1.95
P/E
-4.20
Volume
1.25M
Outstanding Shares
274.75M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 78.77%Revenue (TTM): -28.34%FCF (TTM): -204.93%P/E: 0th pct
What changed
The stock rose 78.77% over the last year. Revenue declined 28.34% over the trailing twelve months. Operating margin moved from -90.91% to -3.63%. Free cash flow declined 204.93% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -3.63%. A decisive move in revenue — currently down 28.34% — would be the clearest signal to resolve the ambiguity.
Company profile
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally.
CEOBernd Brust
SectorHealthcare
IndustryBiotechnology
Employees570
IPO dateNov 20, 2020
Valuation
Forward P/E—
EV/EBITDA-4.87
Enterprise value$716.28M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth-11.59%
Gross margin17.98%▼56.98%vs FY2024
Operating margin-3.63%▲96.01%vs FY2024
ROE-61.58%▼38.28%vs FY2024
Analyst consensus
RatingBuy
Target price$4.50▲18.73%
7
Buy
6
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.05 · Revenue est $53M
View